Brentuximab Vedotin (BV) in Combination with Lenalidomide (len) and Rituximab (R) in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): Results from the Phase 3 ECHELON-3 Study
Clinical Lymphoma Myeloma and Leukemia(2024)
Key words
ABCL,Diffuse large B-cell lymphoma,relapsed/refractory,phase 3
AI Read Science
Must-Reading Tree
Example

Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined